| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7e87f29e0db9416800cab4f60f6c468 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426 |
| filingDate |
2014-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3c40f064d415cc2336052943e9436df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15ec8b5bdb5fc987c51cc4f3eeedfcf2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95a63861b5d50ac48e32850df7b6def7 |
| publicationDate |
2017-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2017078023-A |
| titleOfInvention |
Pharmaceutical composition for oral administration |
| abstract |
Kind Code: A1 A single preparation comprising a controlled release portion containing mirabegron or a pharmaceutically acceptable salt thereof and an immediate release portion containing solifenacin or a pharmaceutically acceptable salt thereof in a clinical setting. In providing, (1) providing a single preparation that suppresses the formation of related substances during storage of each drug. (2) To provide a single preparation that suppresses changes in the dissolution rate of mirabegron during storage. The pharmaceutical composition for oral administration of the present invention comprises (1) a controlled release part containing mirabegron or a pharmaceutically acceptable salt thereof, and (2) solifenacin or a pharmaceutically acceptable salt thereof. And a rapid release part containing a pharmaceutical additive that improves the stability of mirabegron or a pharmaceutically acceptable salt thereof. [Selection figure] None |
| priorityDate |
2014-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |